Stock Analysis of Alpine Immune Sciences Inc (ALPN)

Loading ...

Birds Eye View of Alpine Immune Sciences Inc

Birds's Eye

Technical Analysis of Alpine Immune Sciences Inc

Stock Analysis of Alpine Immune Sciences Inc (ALPN) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	ALPN
Close	64.97
Change	0.0100 / 0.0154 %
Volume	4285.63 K
Vol Change	3550.44 K / 482.93 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Bullish
Growth Index	No Significant Growth
Value Index	Poor Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Low Stability Stock

Fundamental View of Alpine Immune Sciences Inc

PE (TTM)

-21259.02

Very Poor

Price / Book

3343.32

Very Poor

Price / Sales

13854.98

Very Poor

Piotroski F Score

3.0

Not Good

Market Cap

4456.78 M

Enterprise Value

4413.77 M

All Financial Ratio's

ROA (TTM)

-12.21

Very Poor

ROE (TTM)

-15.86

Very Poor

Net Margin (TTM)

-65.17

Very Poor

Revenue

2.44 %

30799.00 K

Net Profit

1.31 %

-57008.00 K

Debt to Equity

0.0028

Excellent

Altman Z Score

51.07

Excellent

Quick Ratio

7.87

Excellent

Cash Ratio

7.80

Excellent

Financial Statement Analysis

Highs/Lows of Alpine Immune Sciences Inc

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	64.94	0.0462 %	1.54 %	65.0	64.92	17-May-24	13-May-24
Two Week	64.6	0.573 %	3.42 %	65.0	64.5	17-May-24	06-May-24
One Month	64.46	0.791 %	5.60 %	65.0	64.4	17-May-24	19-Apr-24
Three Month	31.26	107.84 %	5.95 %	65.0	29.56	17-May-24	21-Feb-24
Six Months	13.38	385.58 %	17.48 %	65.0	13.3	17-May-24	21-Nov-23
One year	8.58	657.23 %	27.52 %	65.0	8.33	17-May-24	26-Oct-23
Two year	8.0	712.12 %	29.70 %	65.0	4.82	17-May-24	24-Oct-22
Five year	5.95	991.93 %	85.46 %	65.0	2.05	17-May-24	19-Mar-20

Technical View of Alpine Immune Sciences Inc

RSI

83.31

Mild Bearish

MACD

3.21

Bearish

ADX

65.05

Strong Bullish

Super Trend

63.78

Mild Bullish

Williams %R

-6.00

Mild Bearish

CCI

118.57

Bearish

Technical Analysis Deep Dive

EMA 5

64.94

Bullish

EMA 15

64.11

Bullish

EMA 50

54.36

Bullish

EMA 100

43.59

Bullish

SMA 100

39.37

Bullish

SMA 200

26.27

Strong Bullish

SMA 5 / 20

64.96 / 64.72

Mild Bullish

SMA 15 / 50

64.77 / 52.49

Bullish

SMA 50 / 200

52.49 / 26.27

Strong Bullish

MA Analysis Deep Dive

Charts of Alpine Immune Sciences Inc

Returns of Alpine Immune Sciences Inc with Peers

Period / Stock	ALPN	IMVT	SYNH	SEM
1 Week	0.0462%	4.46%	0.468%	1.07%
1 Mth	0.791%	7.98%	1.15%	27.49%
3 Mth	107.84%	-17.32%	2.63%	25.05%
6mth	385.58%	-9.23%	23.01%	46.21%
1 Year	657.23%	45.36%	-7.57%	20.99%
2 Year	712.12%	648.78%	-54.50%	34.19%
5 Years	991.93%	-	-15.73%	131.11%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Alpine Immune Sciences Inc with Peers

Ratio / Stock	ALPN	IMVT	SYNH	SEM
PE	-21259.02	-4568.61	61.40	15.89
P/B	3343.32	2769.21	1.28	2.72
ROA	-12.21	-54.91	0.873	3.45
ROE	-15.86	-60.61	2.08	20.99
Debt To Equity	0.0028	0.0032	0.767	3.05
Revenue	30799.00 K 2.44 %	0 %	5393.08 M 3.46 %	6586.66 M 4.00 %
Net Income	-57008.00 K 1.31 %	-210960.00 K 34.60 %	266497 K 13.48 %	224726 K 41.34 %

Technicals of Alpine Immune Sciences Inc with Peers

Technical / Stock	ALPN	IMVT	SYNH	SEM	-
ADX	65.05	19.98	37.31	38.53
CMF	0.115	-0.0275	-0.074	0.451
MFI	71.81	78.76	67.86	90.25
RSI	83.31	55.93	72.61	71.19
MACD Abv Signal	False	True	True	True
Price Above 50 MA	True	True	True	True	-
Price Above 200 MA	True	False	True	True	-

About : Alpine Immune Sciences Inc

Address : 188 East Blaine Street, Seattle, WA, United States, 98102
Tel : 206 788 4545
URL : https://www.alpineimmunesciences.com
Code : ALPN, ISIN : US02083G1004, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 17_Jun_2015
Employee Count : 142

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Note : All Data Generated at the End of Trading Hours (EOD Data)